Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd., has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement, which expands an existing customer relationship, includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms.
The engagement covers development and clinical manufacturing services for an investigational oncology product. Revenue from the agreement is expected during 2026 and 2027, with stability services extending beyond 2027. Following the agreement, Scinai’s committed customer orders across its Jerusalem and Yavne operations reached approximately $7.6 million, up 300% from $1.9 million at year-end 2025 and more than double the $3.1 million reported in August 2026.
The agreement also presents potential additional clinical manufacturing opportunities with an indicative, uncommitted value of $5.85 million for late 2027 through the first half of 2028, subject to further agreements and development milestones. This significant increase in committed orders underscores the growing demand for Scinai’s CDMO services and its ability to secure repeat business from existing clients.
For investors, the news highlights Scinai’s expanding revenue base and the potential for further growth as it continues to build its CDMO business. The company’s dual focus on therapeutic development and contract manufacturing provides multiple avenues for value creation. The full press release can be accessed at https://ibn.fm/5jaNp.
Scinai Immunotherapeutics is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. Its CDMO segment, Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
The announcement was distributed through MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
For more information about MissionIR, visit www.MissionIR.com. Terms of use and disclaimers applicable to all content provided by MissionIR are available at https://www.MissionIR.com/Disclaimer.
